Skip to content

Site logo

Main menu
  • Company
    • Company overview
    • Stories
    • History
    • Environmental, Social & Governance (ESG)
      • ESG overview
      • Philanthropy
      • Merck Medical Outreach Program
      • Impact investing
      • Transparency disclosures
      • ESG resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct & compliance
    • Diversity & inclusion
    • Policies & positions
    • Business development & licensing
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardio-metabolic disorders
    • Pipeline
    • Discovery & development
    • R&D locations
    • Clinical trials
      • Clinical trials overview
      • Find a trial
      • Diversity in clinical trials
  • Products
    • Products list
    • Safety data sheets
    • Product patents
    • Merck authorized distributors
  • Patients
    • Patients overview
    • Patient support programs
    • Patient resources
    • Patient & treatment education
  • Careers
    • Careers
    • Search jobs
    • Our divisions
      • Research & development
      • Manufacturing & supply
      • Human Health
      • Animal Health
      • Global support functions
    • Veterans
    • Student opportunities
    • Compensation & benefits
    • How we hire
    • MSD Careers
    • Events
    • Talent community
  • Investors
    • Investors overview
    • Events & presentations
    • Financial information
      • Financial information overview
      • SEC filings
    • Stock information
    • Investor resources
      • Investor resources overview
      • Organon resources
      • Request for information
  • Media
    • Media overview
    • News releases
    • Company statements
    • Media library & contacts
    • Company fact sheet
two scientists wearing masks

Our COVID-19 efforts

Learn more
Contact us

Worldwide Countries outside of the United States and Canada.

What can we help you find?

Search for:
Environmental, Social & Governance

Our partnerships help make vaccines accessible worldwide

How our colleagues are collaborating with organizations to improve global vaccination rates

October 11, 2022

Share this article

group of men and women smiling

Providing vaccines to some of the hardest-to-reach places around the world

We’re steadfast and dedicated to discovering, developing, supplying and delivering vaccines to help prevent diseases around the world. However, we alone can’t achieve the broadest possible access and distribution to our vaccines.

That’s why we work with governments, international health and development organizations, donor groups, nongovernmental organizations, and others to create new ways to improve vaccine access. And because every community is different, we commit to working with organizations that are a part of those communities to help make certain diseases a thing of the past.

We’ve made great progress, but we know we can do more.

article quote image

"We’re resolute in our goal to ensure the advancement and delivery of medicines and vaccines to help save and improve lives around the world.”

Andrew “Drew” Otoo, PharmD

President, global vaccines

“Through our various partnerships, I’ve witnessed the power of the private sector in bringing affordable and accessible medical services, treatments and diagnostics directly to people globally,” said Dr. Otoo.

We’re committed to fighting vaccine-preventable diseases and boosting global vaccination rates

We have teams around the world working to better understand and help solve the unique challenges communities face in securing access to the right medicines and vaccines with life-saving potential.

“To expand our reach, we need to reimagine how we do business. Through partnerships, we’re figuring out new models to build valued customer relationships, develop new access-focused models and reach new populations that otherwise wouldn’t have had access to our vaccines,” said Abdullahi Sheriff, associate vice president, market access, Merck. 

Our global vaccine partnerships at work

Ghana

people sitting at large table working

To expand vaccine supply in this West African country, we’re partnering with mPharma, a health care data and analytics service organization and the fastest growing provider of fully integrated health care services, medicines, diagnostics and vaccines in Africa.

“I’m proud of the work by mPharma,” said Dr. Otoo, who is Ghanaian-American. “There is much work to be done, but with leaders like these, it’s impossible not to get excited about what lies ahead in advancing the delivery of medicines, medical services, diagnostics and surveillance with dignity and pride across Africa.”

Brazil

Our partnership with Dr. Consulta, a company that offers access to high-quality health care at a low cost in Brazil, started as a trial to understand if it was possible to reach new population segments.

We were delighted to witness improved access to vaccines through their channels.

“If a channel does not exist, an individual has no means to get a vaccine or medicine. Partners can play an important role in addressing these access challenges,” said David Marschner, executive director, market access, Merck.

“It is our hope that insights shared from these novel partnerships will support innovative solutions that will contribute to resilient and sustainable vaccination programs worldwide.”

group of people smiling

Southeast Asia

We’re also working with and exploring a range of opportunities in Indonesia, the Philippines, Singapore and other locations to reach people where we have not yet supplied our vaccines.

We look forward to forging new partnerships in support of our purpose of using the power of leading-edge science to help save and improve lives around the world.

Discover more stories

Pride, pediatrics and parenting

New podcast: Meet the dealmakers 

One scientist’s commitment to dengue fever research

View all stories

Explore more in

Corporate responsibility
Infectious diseases
Vaccines

Related links

related content image #1

Infectious diseases

We play an important role in discovering and developing innovative medicines and vaccines to treat and prevent infectious diseases, including HIV and Ebola

related content image #2

Vaccines

Our work in vaccines focuses on making certain diseases a thing of the past.

related content image #3

Discovery & development

Learn how we bring creative minds together as we aim to turn world-class research into impactful medicines and vaccines

Connect with us on social

social icon social icon social icon social icon social icon
  • MerckHelps
    Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients
  • Merck Access Program
    Information about insurance coverage and financial assistance options for eligible patients
  • Clinical trials
    Learn about our clinical trials and find available studies
  • Merck Manuals
    Medical information source covering thousands of topics in all fields of medicine
  • Environmental, Social & Governance (ESG) Report
    Reporting on our commitment to operating responsibly to benefit society
  • Merck for Mothers
    An initiative to create a world where no woman has to die giving life
  • Merck Animal Health
    The global animal health business unit of Merck
  • Health Plan - Transparency in Coverage
    In compliance with the Consolidated Appropriations Act, learn more about our health plan's pricing information.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Transparency disclosure
  • Terms of use
  • Accessibility
  • Sitemap
Copyright © 2023 Merck & Co., Inc., Rahway, NJ USA, and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.
Accessibility icon View Privacy Shield Verification Status View APEC CBPR Privacy Certification Status

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

You are leaving Merck.com

Continue

Welcome to Merck.com

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.

Continue